ELVN
Price:
$21.44
Market Cap:
$1.01B
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.[Read more]
Industry
Biotechnology
IPO Date
2020-03-12
Stock Exchange
NASDAQ
Ticker
ELVN
According to Enliven Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.23. This represents a change of 23.05% compared to the average of -9.13 of the last 4 quarters.
The mean historical PE Ratio of Enliven Therapeutics, Inc. over the last ten years is -8.46. The current -11.23 PE Ratio has changed 13.18% with respect to the historical average. Over the past ten years (40 quarters), ELVN's PE Ratio was at its highest in in the December 2022 quarter at 0.84. The PE Ratio was at its lowest in in the June 2020 quarter at -46.56.
Average
-8.46
Median
-6.87
Minimum
-22.86
Maximum
0
Discovering the peaks and valleys of Enliven Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 407.57%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -22.86
Year | PE Ratio | Change |
---|---|---|
2023 | -6.87 | 407.57% |
2022 | -1.35 | 61.25% |
2021 | -0.84 | -94.82% |
2020 | -16.22 | 46.78% |
2019 | -11.05 | -51.68% |
2018 | -22.86 | -Infinity% |
The current PE Ratio of Enliven Therapeutics, Inc. (ELVN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-3.02
5-year avg
-7.27
10-year avg
-8.46
Enliven Therapeutics, Inc.’s PE Ratio is less than Theseus Pharmaceuticals, Inc. (-3.19), less than PMV Pharmaceuticals, Inc. (-1.58), less than Cullinan Oncology, Inc. (-6.96), less than Immuneering Corporation (-0.62), less than Aerovate Therapeutics, Inc. (-0.62), greater than MoonLake Immunotherapeutics (-52.80), greater than Structure Therapeutics Inc. (-18.15), less than Compass Therapeutics, Inc. (-4.30), less than Replimune Group, Inc. (-3.26), less than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58), less than Gossamer Bio, Inc. (-2.55), less than Eliem Therapeutics, Inc. (-3.49), less than Inhibrx, Inc. (0.13), less than Merrimack Pharmaceuticals, Inc. (-8.92), less than Celcuity Inc. (-7.01),
Company | PE Ratio | Market cap |
---|---|---|
-3.19 | $181.50M | |
-1.58 | $77.28M | |
-6.96 | $1.04B | |
-0.62 | $34.99M | |
-0.62 | $54.85M | |
-52.80 | $2.89B | |
-18.15 | $2.11B | |
-4.30 | $196.75M | |
-3.26 | $708.49M | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M | |
-2.55 | $205.87M | |
-3.49 | $495.57M | |
0.13 | $218.01M | |
-8.92 | $223.97M | |
-7.01 | $557.67M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enliven Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Enliven Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Enliven Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Enliven Therapeutics, Inc. (ELVN)?
What is the highest PE Ratio for Enliven Therapeutics, Inc. (ELVN)?
What is the 3-year average PE Ratio for Enliven Therapeutics, Inc. (ELVN)?
What is the 5-year average PE Ratio for Enliven Therapeutics, Inc. (ELVN)?
How does the current PE Ratio for Enliven Therapeutics, Inc. (ELVN) compare to its historical average?